- Switzerland
- /
- Life Sciences
- /
- SWX:LONN
Lonza Group First Half 2024 Earnings: Revenues Beat Expectations, EPS In Line
Lonza Group (VTX:LONN) First Half 2024 Results
Key Financial Results
- Revenue: CHF3.06b (flat on 1H 2023).
- Net income: CHF329.0m (down 20% from 1H 2023).
- Profit margin: 11% (down from 13% in 1H 2023).
- EPS: CHF4.61 (down from CHF5.54 in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Lonza Group Revenues Beat Expectations
Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) was mostly in line with analyst estimates.
Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Life Sciences industry in Switzerland.
Performance of the Swiss Life Sciences industry.
The company's shares are up 12% from a week ago.
Risk Analysis
You should learn about the 2 warning signs we've spotted with Lonza Group.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SWX:LONN
Lonza Group
Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
Excellent balance sheet with reasonable growth potential.